The total results of a prior randomized, active-controlled Phase IIb study display that the novel, targeted therapy holds significant promise. Currently recruiting study centers will be published on.. Antisense Pharma’s SAPPHIRE Stage III trial evaluating trabedersen approved by Wellness Canada Research to examine trabedersen vs. Current regular chemotherapy in sufferers with recurrent or refractory anaplastic astrocytoma The biopharmaceutical organization Antisense Pharma GmbH offers announced today that it offers received the acceptance by Health Canada for its pivotal Phase III scientific trial SAPPHIRE in individuals with recurrent or refractory anaplastic astrocytoma. The SAPPHIRE research can be a randomized, active-managed, clinical trial made to confirm the efficacy and security of the investigational drug trabedersen , observed in previous clinical research.‘Reducing the burden of Alzheimer’s disease on sufferers and their families is an urgent national priority,’ Human and Health Solutions Secretary Kathleen Sebelius said. Given the nation’s financial problems, it isn’t clear if Congress will approve a increase in following year’s Alzheimer’s funding. But for this year, Collins said Alzheimer’s is usually such a priority that the NIH will change some of its budget from other study areas to eke out an extra $50 million immediately.